Rare diseases specialist Swedish Orphan Biovitrum has appointed Anne Marie de Jonge Schuermans as head of its new Technical Operations organization, bringing together Sobi’s manufacturing operations/biological development and supply, quality, supply chain, procurement and environment and safety operations.
Ms de Jonge Schuermans will join on October 1, 2018, and be part of Sobi’s Executive Committee. She joins Sobi from Biogen (Nasdaq: BIIB) where she served as vice president for global supply chain operations and strategic partnerships and as an executive board member of Biogen International GmbH.
Ms de Jonge Schuermans brings more than 15 years of experience in the healthcare industry from Biogen, Stryker and Novartis. She has a track record of putting processes and systems in place, and of driving transformation in cross-functional and cross-cultural settings.
Ms de Jonge Schuermans says: “Sobi has unique capabilities, a heritage in biologics manufacturing, development and supply, and a very exciting future within the rare disease space. I look forward to working with the teams to develop an effective and agile organization set for growth.”
Source: The Pharma Letter
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.